Exom Group

15/04/2024

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀: 𝗢𝘂𝗿 𝗡𝗲𝘄 𝗣𝗿𝗼𝗳𝗶𝗹𝗲 𝗨𝗻𝗹𝗲𝗮𝘀𝗵𝗲𝗱!

𝘎𝘦𝘵 𝘳𝘦𝘢𝘥𝘺 𝘧𝘰𝘳 𝘢 𝘧𝘳𝘦𝘴𝘩 𝘴𝘵𝘢𝘳𝘵 𝘢𝘴 𝘸𝘦 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘱𝘳𝘰𝘧𝘪𝘭𝘦 𝘵𝘰 𝘢 𝘯𝘦𝘸 𝘩𝘰𝘮𝘦, 𝘳𝘦𝘧𝘭𝘦𝘤𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘧𝘪𝘯𝘢𝘭 𝘴𝘵𝘢𝘨𝘦𝘴 𝘰𝘧 𝘰𝘶𝘳 𝘮𝘦𝘳𝘨𝘦𝘳 𝘸𝘦 𝘴𝘵𝘢𝘳𝘵𝘦𝘥 𝘣𝘢𝘤𝘬 𝘪𝘯 2023. 𝘚𝘵𝘢𝘺 𝘵𝘶𝘯𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘷𝘪𝘣𝘳𝘢𝘯𝘵 𝘧𝘶𝘵𝘶𝘳𝘦, 𝘦𝘯𝘨𝘢𝘨𝘪𝘯𝘨 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘢𝘯𝘥 𝘦𝘹𝘤𝘪𝘵𝘪𝘯𝘨 𝘯𝘦𝘸𝘴 𝘢𝘵 𝘵𝘩𝘦 𝘯𝘦𝘸 𝘱𝘳𝘰𝘧𝘪𝘭𝘦 𝘰𝘧 𝘒𝘢𝘱𝘢𝘥𝘪!

Dear Valued Followers,

Get ready to witness the grand transformation as our beloved 𝗘𝘅𝗼𝗺 𝗚𝗿𝗼𝘂𝗽 profile locks its doors and triumphantly emerges on the vibrant new stage as 𝗞𝗔𝗣𝗔𝗗𝗜: 𝗧𝗵𝗲 𝗣𝗿𝗲𝗺𝗶𝗲𝗿 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗖𝗥𝗢!

Under the banner of KAPADI, we proudly gather all our scattered profiles, uniting under a single, dynamic hub. Your precious subscriptions will seamlessly migrate to our new digital home, ensuring that you won't miss a beat of our engaging content.

We cherish the memories and connections forged on this platform and pledge to carry that same spirit forward into our new chapter. Stay tuned for even more insightful explorations, thought-provoking discussions, and valuable resources tailored to your needs!

Our doors may be closing on this old profile, but the conversation continues on our captivating new platform. Engage with us directly, share your thoughts, and let's paint a vibrant future together!

01/01/2024

Cheers to a new year filled with success, innovation, and opportunities! Here’s wishing our esteemed clients, partners and colleagues a very happy and prosperous 2024. May this year bring you endless joy and numerous accomplishments. Looking forward to working with you in 2024.

21/12/2023

As the year comes to a close, we find ourselves reflecting on the past twelve months, cherishing the valuable partnerships we've formed, and remembering all those unforgettable moments we've shared with our incredible team. As we usher in 2024, it is our hope that this season of joy brings you peace, prosperity, and even more reasons to smile. From everyone at Exom Group – Here's wishing you a heartwarming Holiday Season and an inspiring start to 2024!

27/11/2023

Counting down! Just 12 days until the American Society of Hematology annual meeting! We're eagerly looking forward to engaging with top-tier industry experts & showcasing our deep-rooted knowledge in hematology. Don't miss your chance to meet our specialist, Martha - she'll be there to answer your questions on hematology clinical trials. Excitement is in the blood!

Schedule your meeting at MeetOncoBay@OncoBay.com

09/10/2023

Accelerating the future of clinical trials! Exom Group, in collaboration with AWS Partner Storm Reply, has automated remote patient consent with -powered chatbot technology. This digital revolution bypasses the need for in-person informed consent and boosts participation rates by allowing easy access through email and text.

Explore this life-saving innovation here: https://sqr.co/aws-vEngage/

05/04/2023

It's national cancer control awareness month in the US. However, I think this should be a global event as cancer is one of the leading death causes worldwide. Early detection and diagnosis can help to survive. Together, the Grupa NEUCA companies, consisting of Clinscience – the #1 global SMART CRO you need!, Exom Group and OncoBay Clinical, we are at the forefront of cancer research, supporting and companies on their pursuit of curing cancer. I am proud to be part of this group.

It's national cancer control awareness month in the US. However, I think this should be a global event as cancer is one of the leading death causes worldwide…

20/03/2023

Together, we are working towards a brighter future for those living with inherited arrhythmogenic cardiomyopathy (ACM). With the support of the European Union and leading experts in preclinical research and cardiac genetics, we are proud to be part of the Geremy project – a project seeking a genetic cure for ACM. Read more at https://swiy.co/EXG-GEREMY

01/02/2023

Experience the difference with Exom Group. Our technology- and data-driven approach utilizes innovative technologies and advanced analytics to optimize clinical trial conduction. Get faster results, save money, and improve patient recruitment and retention with us. Learn more at www.exomgroup.com today!

20/12/2022

It's the time of the year when you get ready for the holidays. The entire team at Exom Group sends warm winter wishes to all our valued customers. We hope this holiday season will bring you joy and happiness. Stay safe where ever you are. We look forward to a successful 2023.

05/12/2022

The future of clinical trials is here with Genius vENGAGE.
Genius vENGAGE is the first “verbal consent” for remote patient engagement in clinical trials. Learn more at www.exomgroup.com or contact us.

14/11/2022

Exom Group, a Clinscience company, is proud to announce the release of the first patient-centric “reliable & compliant” remote verbal consent for clinical trials (Genius vENGAGE).

Read our latest news at bit.ly/verbalconstent

14/10/2022

Thanks, everyone who joined our Webinar on Budgeting & Ex*****on: The impact of a Unified, Digital Ecosystem and Real-Time Data Analytics."

In case you missed it, you can watch the recorded webinar here: https://jubb.ly/964ea5

Join this webinar to learn how a fully unified digital ecosystem impacts trial management and how novel approaches influence clinical trial budgeting.

15/07/2022

The ATLAS sponsored by the Polish Myeloma Consortium & managed by was announced winner in the elite group "Best of ASCO" 2022.

Read the Article: https://jubb.ly/a17eea and Blog: https://jubb.ly/e42632

04/07/2022

Happy 4th of July to all our American Clients. Enjoy celebrating Independence Day.

"We must be free not because we claim freedom, but because we practice it."
— William Faulkner.

20/05/2022

have become more efficient and less time-consuming than ever with innovative technologies. New technologies allow for a patient-centric approach when designing a study. This leads to an increasing number of patients applying for clinical trials.

Today on the we want to celebrate these achievements. We thank the entire research community for their commitment to bringing new treatments to the market and improving the lives of millions of patients worldwide.